ArticleThe Journal of clinical endocrinology and metabolism2014
Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study.
Article in The Journal of clinical endocrinology and metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 5 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- Risk of intracranial meningioma in patients with acromegaly: a systematic review.Frontiers in endocrinology · 2024Pooled it
- Management of incidental brain tumors in children: a systematic review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2020Pooled it
- The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke.Endocrine · 2017Pooled it
- Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review.Endocrine-related cancer · 2016Pooled it
- Growth hormone therapy and risk of recurrence/progression in intracranial tumors: a meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2015Pooled it
- Endocrine late-effects in survivors of childhood and adolescence cancer: clinical management.Journal of endocrinological investigation · 2026Review
- Navigating the Complexities of Radiation Injuries: Therapeutic Principles and Reconstructive Strategies.Journal of personalized medicine · 2024Review
- Article
- Growth hormone and radiation therapy: friend, foe, or both?Endocrine-related cancer · 2024Review
- Developments in the Management of Growth Hormone Deficiency: Clinical Utility of Somapacitan.Drug design, development and therapy · 2024Review
- The Advantage of Growth Hormone Alone as an Adjuvant Therapy in Advanced Age and BMI ≥ 24 kg/mJournal of clinical medicine · 2023Article
- Long-Term Safety of Growth Hormone Deficiency Treatment in Cancer and Sellar Tumors Adult Survivors: Is There a Role of GH Therapy on the Neoplastic Risk?Journal of clinical medicine · 2023Review
- Influence of growth hormone therapy on germinoma survivors.Pituitary · 2022Article
- Growth Hormone Deficiency in Childhood Intracranial Germ Cell Tumor Survivors.Journal of endocrinology and metabolism · 2022Article
- Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement.European journal of endocrinology · 2022Review
- Association Between Recombinant Growth Hormone Therapy and All-Cause Mortality and Cancer Risk in Childhood: Systematic Review and Meta-Analysis.Frontiers in pediatrics · 2022Article
- Pediatric and Adult Low-Grade Gliomas: Where Do the Differences Lie?Children (Basel, Switzerland) · 2021Review
- Review
- Clinical Outcomes and Complications of Pituitary Blastoma.The Journal of clinical endocrinology and metabolism · 2021Observational
- Endocrine Complications in Children and Adolescents With Non-Central Nervous System Solid Tumors.Frontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 2 countries.
Funding
Abstract
contextCranial radiation therapy (CRT) predisposes to GH deficiency and subsequent neoplasms (SNs) of the central nervous system (CNS). Increased rates of SNs have been reported in GH-treated survivors.
objectiveThe objective of the study was to evaluate the association between GH treatment and the development of CNS-SNs.
designThe study was designed with a retrospective cohort with longitudinal follow-up.
settingThe setting of the study was multiinstitutional.
participantsA total of 12 098 5-year pediatric cancer survivors from the Childhood Cancer Survivor Study, diagnosed with cancer prior to age 21 years, of whom 338 self-reported GH treatment, which was verified through medical record review.
interventionsINTERVENTIONS included subject surveys, medical records abstraction, and pathological review. OUTCOME MEASURES: Incidence of meningioma, glioma, and other CNS-SNs was measured.
resultsAmong GH-treated survivors, 16 (4.7%) developed CNS-SN, including 10 with meningioma and six with glioma. Two hundred three survivors without GH treatment (1.7%) developed CNS-SN, including 138 with meningioma, 49 with glioma, and 16 with other CNS-SNs. The adjusted rate ratio in GH-treated compared with untreated survivors for development of any CNS-SN was 1.0 [95% confidence interval (CI) 0.6-1.8, P = .94], for meningiomas, 0.8 (95% CI 0.4-1.7, P = .61), and for gliomas, 1.9 (95% CI 0.7-4.8, P = .21). Factors associated with meningioma development included female gender (P = .001), younger age at primary cancer diagnosis (P < .001), and CRT/longer time since CRT (P < .001). Glioma was associated with CRT/shorter time since CRT (P < .001).
conclusionsThere was no statistically significant increased overall risk of the occurrence of a CNS-SN associated with GH exposure. Specifically, occurrence of meningiomas and gliomas were not associated with GH treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.